Literature DB >> 18306349

Tissue hepatitis C virus RNA quantification and protein expression help identify early hepatitis C virus recurrence after liver transplantation.

Antonia D'Errico-Grigioni1, Michelangelo Fiorentino, Francesco Vasuri, Elisa Gruppioni, Benedetta Fabbrizio, Nicola Zucchini, Giorgio Ballardini, Cristina Morelli, Antonio Daniele Pinna, Walter Franco Grigioni.   

Abstract

We compared tissue hepatitis C virus (HCV) RNA polymerase chain reaction quantification and HCV immunohistochemistry (IHC) to histology in biopsy tissues in order to differentiate between acute rejection and HCV hepatitis recurrence early after orthotopic liver transplantation (OLT). We analyzed the first biopsy performed because of alteration of serum aminotransferases in 65 consecutive OLT patients with HCV genotype 1b. In the histological analysis, we quantified the portal tracts, Councilman bodies, Councilman body/portal tract (CP) ratio, steatosis, and Knodell and Ishak scores. The 52 patients (80%) with histological HCV recurrence [recurrence-positive (Rec+)] were separated from the 6 (9%) with acute rejection and the 7 (11%) with undetermined pathological features [recurrence-negative (Rec-)]. HCV RNA strongly correlated with HCV IHC, regardless of the histological diagnosis (P < 0.001). Both HCV RNA and HCV IHC were significantly associated with CP ratio (P = 0.041 and P = 0.008). No statistical correlation was found between HCV RNA, HCV IHC, and the other histopathologic features or the hepatitis scores. HCV RNA, HCV IHC, and CP ratio were the only variables able to discriminate between Rec+ and Rec- patients (Mann-Whitney test P < 0.001, P < 0.001, P = 0.014). In conclusion, a combined evaluation of histology, tissue HCV RNA, and HCV IHC significantly discriminated between OLT patients with or without HCV recurrence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18306349     DOI: 10.1002/lt.21375

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  5 in total

1.  Molecular pathways differentiate hepatitis C virus (HCV) recurrence from acute cellular rejection in HCV liver recipients.

Authors:  Ricardo Gehrau; Daniel Maluf; Kellie Archer; Richard Stravitz; Jihee Suh; Ngoc Le; Valeria Mas
Journal:  Mol Med       Date:  2011-04-20       Impact factor: 6.354

Review 2.  Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review.

Authors:  Francesco Vasuri; Deborah Malvi; Elisa Gruppioni; Walter F Grigioni; Antonia D'Errico-Grigioni
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

3.  Quantification of C4d deposition and hepatitis C virus RNA in tissue in cases of graft rejection and hepatitis C recurrence after liver transplantation.

Authors:  Alice Tung Wan Song; Evandro Sobroza de Mello; Venâncio Avancini Ferreira Alves; Norma de Paula Cavalheiro; Carlos Eduardo Melo; Patricia Rodrigues Bonazzi; Fatima Mitiko Tengan; Maristela Pinheiro Freire; Antonio Alci Barone; Luiz Augusto Carneiro D'Albuquerque; Edson Abdala
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-02-13       Impact factor: 2.743

Review 4.  Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.

Authors:  Alberto Grassi; Giorgio Ballardini
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

5.  Abrogation of TNFα production during cancer immunotherapy is crucial for suppressing side effects due to the systemic expression of IL-12.

Authors:  Bibiana Barrios; Natalia S Baez; Della Reynolds; Pablo Iribarren; Hugo Cejas; Howard A Young; Maria Cecilia Rodriguez-Galan
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.